Responders (N = 85) | Non-responders (N = 10) | |||||
---|---|---|---|---|---|---|
Before anti-TNF treatment | After anti-TNF treatment | P | Before anti-TNF treatment | After anti-TNF treatment | P | |
Clinical assessments | ||||||
TJC | 15.9 ± 4.8 | 5.1 ± 2.2 | 0.000 | 15.6 ± 5.1 | 8.5 ± 2.9 | 0.005 |
SJC | 11.7 ± 3.9 | 2.9 ± 1.8 | 0.000 | 11.6 ± 4.9 | 5.1 ± 2.7 | 0.005 |
DAS28 | 5.8 ± 0.6 | 3.3 ± 0.7 | 0.000 | 5.5 ± 0.7 | 4.3 ± 0.6 | 0.005 |
SDAI | 36.3 ± 11.4 | 2.9 ± 6.8 | 0.000 | 39.2 ± 11.8 | 5.7 ± 12.1 | 0.005 |
HAQ | 2.1 ± 0.3 | 1 ± 0.4 | 0.000 | 2.1 ± 0.3 | 1 ± 0.3 | 0.008 |
Serological assessments | ||||||
ESR (mm/h) | 56.4 ± 17.2 | 27.9 ± 18.5 | 0.000 | 51.4 ± 11.9 | 37.6 ± 19.3 | ns |
CRP (mg/L) | 3.9 ± 2.1 | 1.5 ± 1.2 | 0.000 | 2.2 ± 0.8 | 2.5 ± 0.9 | ns |
RF (U/L) | 155.2 ± 288.3 | 85.4 ± 241 | 0.000 | 61.2 ± 84.3 | 20.8 ± 39.9 | 0.027 |
IL-6 (pg/mL) | 9.4 ± 46.7 | 1.4 ± 6.8 | 0.000 | 2.1 ± 5.6 | 0 | ns |
TNF (pg/mL) | 14.9 ± 28.8 | 5.7 ± 6.1 | 0.038 | 4.1 ± 4.5 | 4.7 ± 5.1 | ns |
sTNFRII (pg/mL) | 1.5 ± 0.9 | 1.5 ± 0.7 | ns | 1.3 ± 0.4 | 1.5 ± 0.7 | ns |
MCP-1 (pg/mL) | 1174.8 ± 1615.4 | 1216.4 ± 1655.4 | ns | 740 ± 504.6 | 678.6 ± 221.8 | ns |
VEGF (pg/mL) | 1107.7 ± 1360.9 | 830.3 ± 570.1 | ns | 796.7 ± 462.7 | 1077.9 ± 711.6 | ns |
IL23 (pg/mL) | 115 ± 235.5 | 76.8 ± 132.9 | ns | 41.2 ± 30.5 | 223.5 ± 424.8 | ns |
IL22 (pg/mL) | 46.3 ± 112 | 17.2 ± 29.2 | ns | 8.4 ± 8.1 | 104.9 ± 193.3 | ns |
IL17 (pg/mL) | 4.8 ± 8.5 | 2.1 ± 2.1 | 0.024 | 11.9 ± 19.1 | 1.4 ± 1.4 | ns |
IL4 (pg/mL) | 22.8 ± 17.6 | 14.9 ± 16.2 | ns | 4.2 ± 6 | 12.8 ± 18.2 | ns |